Bumetanide nasal spray is bioequivalent to oral bumetanide in 68 healthy adults; Esperion is targeting heart failure care before a 2027 CMS payment model.
|Articles|March 16, 2012
CBO: Health Reform Could Cause People to Lose Workplace Coverage
Advertisement
A new report from the Congressional Budget Office hands critics of the health reform law a great new talking point: Under a worst-case scenario, the law could lead to 20 million people losing their employer-sponsored insurance in 2019.
The agency doesn’t think that’s likely, however. The new report, released Thursday, said the agency expects 3 million to 5 million fewer people to have employer coverage each year because of the health reform law. That’s close to the agency’s original estimate, which predicted 3 million people could lose their workplace coverage.
Read the full story:
Source: Politico
Advertisement
Related to this article
The trade group says CMS lacks authority to impose GLOBE, which is set to begin January 1.
Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.
Leukemia survivors given high-risk ALL therapy had hip bone density about 90% of matched controls, without the partial normalization seen in other groups.
A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
Sacral neuromodulation is still considered the gold standard for refractory overactive bladder, with tibial nerve stimulation a less invasive option.
FDA approved tucatinib maintenance for HER2-positive metastatic breast cancer following induction therapy based on the 654-patient HER2CLIMB-05 trial.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know if Retatrutide Is Classified as a Biologic
2
Predoc and Nebraska Cancer Specialists: Not Letting the Fax Be the Fumble
3
Sacral Neuromodulation Still Seen as OAB Gold Standard in Review
4
FDA Approves First Symptomatic Dermographism Treatment
5